John Dawson, Chief Executive Officer of Oxford Biomedica, a leading gene and cell therapy group, has been named Executive of the Year in the category for companies with a market cap below $10 billion at the 16th Annual Scrip Awards 2020.
The Digital Scrip Awards took place on 02 December 2020 and acknowledged the outstanding achievements taking place across the pharmaceutical, biotech and other allied industries, in improving healthcare. Its trophies span the entire range of industry activities, from new drug launches and clinical trials to innovative deals, outsourcing and fundraising.
This Annual Scrip Awards 2020 recognises Oxford Biomedica’s achievements from June 2019 up to the end of May 2020, taking into account the Company’s efforts on the Lentivector® platform and subsequent partnership agreements, which more than doubled in the period from nine to nineteen, including:
- a deal with Juno Therapeutics, a Bristol-Myers Squibb Company,
- the extension of the commercial supply agreement with Novartis for a further five years to work on six programmes, and
- R&D collaboration with Santen to develop gene therapy products inherited retinal disease.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “It is a huge honour to accept this award on behalf of everyone at Oxford Biomedica and this is a true testament to the dedication and hard work demonstrated by everyone at the Company.
“We’ve collectively won this award for our efforts on our Lentivector® platform and deals including Juno Therapeutics, a Bristol-Myers Squibb company, and the Novartis extension. This award is by far the biggest recognition that Oxford Biomedica has received for its achievements in driving gene therapy forward for patients, and as a leader in the space. Congratulations to the other nominees on their work this year, and thank you to Scrip for recognising Oxford Biomedica.”
